Between 17 April and 1 May, the type 2 component of the oral polio vaccine (OPV) is being removed from use through aglobally synchronized switch from the trivalent to bivalent oral polio vaccine. This is the first stage of objective 2 of the Polio Eradication and Endgame Strategic Plan 2013-2018 to withdraw OPV in a phased manner starting with the type 2 component following the eradication of wild poliovirus type 2 in September 2015.
155 of 155 (100%) countries and territories have stopped using the trivalent oral polio vaccine.
Independent monitoring to ensure the switch goes smoothly has begun in 152 countries (100%).
The National Validation Committee has received switch monitoring data in 145 countries (95%).
The WHO Regional Offices has received the National Validation Report from 147 countries (95%).
Wild poliovirus type 1 and Circulating vaccine-derived poliovirus cases
Total in 2015
- in endemic countries
- in non-endemic countries
Case breakdown by country
Total in 2015
Onset of paralysis of most recent case
NA: onset of paralysis in most recent case is prior to 2015. Figures exclude non-AFP sources. Madagascar, Ukraine and Lao PDR cVDPV1, all others cVDPV2. cVDPV definition: see document "Reporting and classification of vaccine-derived polioviruses" at http://www.polioeradication.org/Portals/0/Document/Resources/VDPV_ReportingClassification.pdf. Implementation as of 15 August 2015.
No cases of circulating vaccine-derived poliovirus type 2 (cVDPV2) have been reported in 2016. The most recent case was isolated from a 16-month old child in Maungdaw, Rakhine, with onset of paralysis on 05 October. The total number of cVDPV2 cases in 2015 remains two.
The Global Polio Eradication Initiative © Copyright 2010